{"id":"d738d7c6-c3af-55f5-bfbe-2693c5dca706","stable_key":"ca8e9e6a-6953-51ec-b712-2b06398a416d:ra-furosemide-exposure","predicate":"increases_in_recorded_comparison","statement":"IV RA increased furosemide AUC from 1.52 to 3.30 micromolar h and reduced urinary excretion.","claim_class":"observational","status":"source_recorded","evidence_grade":"ungraded","direction":"positive","is_public":true,"mechanism_event_id":"97b920ba-55b9-5c22-8a54-d4697abf804d","mechanism_event_label":"IV RA increased furosemide AUC from 1.52 to 3.30 micromolar h and reduced urinary excretion.","subject":{"id":"6072a4ae-d563-5466-a1b2-6d280255d346","slug":"rosmarinic-acid","display_name":"Rosmarinic acid","entity_type_key":"small_molecule"},"object":{"id":"498a77ba-adf4-5715-a61c-804879b20390","slug":"rat-furosemide-exposure","display_name":"Rat plasma furosemide exposure","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"97b920ba-55b9-5c22-8a54-d4697abf804d","stable_key":"ca8e9e6a-6953-51ec-b712-2b06398a416d:ra-furosemide-exposure-event","event_type":"experimental_observation","label":"IV RA increased furosemide AUC from 1.52 to 3.30 micromolar h and reduced urinary excretion.","description":"### ra-furosemide-exposure\n\nIV RA increased furosemide AUC from 1.52 to 3.30 micromolar h and reduced urinary excretion.\nOAT3 inhibition is a proposed contributor; transport and clinical diuresis are not the same endpoint.\nModel and exposure: Rats n=4/group; RA 10 mg/kg and furosemide 0.2 mg/kg IV.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: Involvement of Organic Anion Transporters in the Pharmacokinetics and Drug Interaction of Rosmarinic Acid. | 2021 | https://pubmed.ncbi.nlm.nih.gov/33435470/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC7828042/ | https://doi.org/10.3390/pharmaceutics13010083 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"6072a4ae-d563-5466-a1b2-6d280255d346","slug":"rosmarinic-acid","display_name":"Rosmarinic acid","entity_type_key":"small_molecule"},"role":"tested factor","stoichiometry":null,"state_label":"RA plus furosemide","sequence_order":0,"notes":""},{"entity":{"id":"498a77ba-adf4-5715-a61c-804879b20390","slug":"rat-furosemide-exposure","display_name":"Rat plasma furosemide exposure","entity_type_key":"cellular_process"},"role":"measured outcome","stoichiometry":null,"state_label":"increase","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_condition","value_text":"0.2 mg/kg IV","comparator":"Furosemide alone","unit":null,"notes":"Condition belongs to the full experimental contrast; do not separate a joint intervention.","entity":{"slug":"furosemide","display_name":"Furosemide","entity_type_key":"small_molecule"}},{"dimension":"experimental_condition","value_text":"RA plus furosemide","comparator":"Furosemide alone","unit":null,"notes":"Condition belongs to the full experimental contrast; do not separate a joint intervention.","entity":{"slug":"rosmarinic-acid","display_name":"Rosmarinic acid","entity_type_key":"small_molecule"}},{"dimension":"experimental_contrast","value_text":"{\"intervention\": \"RA plus furosemide\", \"comparator\": \"Furosemide alone\", \"endpoint\": \"IV RA increased furosemide AUC from 1.52 to 3.30 micromolar h and reduced urinary excretion.\", \"effect_direction\": \"increase\", \"combination\": \"joint\", \"conditions\": [{\"entity_slug\": \"rosmarinic-acid\", \"state\": \"RA plus furosemide\"}, {\"entity_slug\": \"furosemide\", \"state\": \"0.2 mg/kg IV\"}]}","comparator":null,"unit":null,"notes":"Explicit extracted experimental comparison; recorded from source.","entity":null},{"dimension":"experimental_model","value_text":"Rats n=4/group; RA 10 mg/kg and furosemide 0.2 mg/kg IV.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"interpretation_status","value_text":"Recorded from source with stated access limits; ungraded, not independent replication.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Rosmarinic acid collection; exact intervention and molecular form govern interpretation.","comparator":null,"unit":null,"notes":"","entity":{"slug":"rosmarinic-acid","display_name":"Rosmarinic acid","entity_type_key":"small_molecule"}},{"dimension":"plain_language","value_text":"IV RA increased furosemide AUC from 1.52 to 3.30 micromolar h and reduced urinary excretion.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Involvement of Organic Anion Transporters in the Pharmacokinetics and Drug Interaction of Rosmarinic Acid. | https://pubmed.ncbi.nlm.nih.gov/33435470/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC7828042/ | https://doi.org/10.3390/pharmaceutics13010083","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"source_locator","value_text":"Reviewed reference ra-furosemide-exposure; OAT3 inhibition is a proposed contributor; transport and clinical diuresis are not the same endpoint.","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"78d36e87-22fa-57ae-99cb-d27c242cc37f","evidence_kind":"source_excerpt","locator":"Lines 413-419","start_line":413,"end_line":419,"excerpt":"### ra-furosemide-exposure\n\nIV RA increased furosemide AUC from 1.52 to 3.30 micromolar h and reduced urinary excretion.\nOAT3 inhibition is a proposed contributor; transport and clinical diuresis are not the same endpoint.\nModel and exposure: Rats n=4/group; RA 10 mg/kg and furosemide 0.2 mg/kg IV.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: Involvement of Organic Anion Transporters in the Pharmacokinetics and Drug Interaction of Rosmarinic Acid. | 2021 | https://pubmed.ncbi.nlm.nih.gov/33435470/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC7828042/ | https://doi.org/10.3390/pharmaceutics13010083 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","model_system":"Rats n=4/group; RA 10 mg/kg and furosemide 0.2 mg/kg IV.","directness":"reported_statement","verification_status":"source_recorded","notes":"Original paraphrase in the retained reviewed reference, not a verbatim primary-paper quotation. Access level is explicit.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"606cff22-a6ed-59cd-a84d-87f44c59dc25","stable_key":"import-ca8e9e6a-6953-51ec-b712-2b06398a416d","title":"Rosmarinic acid: detailed mechanisms of action (reviewed 10 October 2026)","document_type":"imported_text","citation_label":"AI-assisted original curation of primary studies; claim-local access and experimental limitations stated. Includes original-draft correction history. No independent replication claimed.","file_path":"","sha256":"684b4eab1dc2c0057f679109770af0de9340af5cd933377b590298cf8a752956","revision_id":"4028d9c5-fb17-54c5-b72c-c6d21678a832","review_status":"source_recorded","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}